Granules India Q1 profit soars 60% to ₹180 crore; balance sheet turns nearly debt-free
Granules India manufactures the raw ingredients and final pills for common medicines—think of paracetamol tablets or ADHD capsules—and sells them to generic and branded drug companies across North America, Europe, and beyond. In the June 2026 quarter, the company reported a 60% year‑on‑year jump in consolidated net profit to ₹179.96 crore, as a deliberate pivot toward complex, high‑barrier generics lifted margins and strengthened cash flows. Revenue grew 22% to ₹1,476.8 crore, and free cash generation helped slash net debt to near zero. The results underscore a structural improvement in earnings quality that is now clearly visible in the numbers.
Complex generics cross the halfway mark, lifting margins
Granules’ Finished Dosages (FD) segment—which makes up 74% of total revenue—saw complex generics (Complex Gx) account for 50% of FD sales in Q1 FY27, up from 39% a year ago and from just 31% at the start of FY26. Complex Gx includes products with high entry barriers such as controlled substances, MUPS‑platform drugs, and CNS/ADHD medications, where limited competition supports stronger pricing and stickier volumes.
“Accelerated growth in Complex Gx products resulting in 50% share of FD from 39% YOY basis,” the company stated in its investor presentation. This mix shift pushed consolidated gross margin to 65.6% and EBITDA margin to 23.1%.
Management has been executing this transition for over four years. On the FY26 earnings call, Chairman K.P. Chigurupati pointed out that gross margin had climbed from 50% in FY22 to 65%. The strategy: move away from volume‑driven, commoditised generics toward products where formulation, API, or IP complexity limits the number of competitors. The R&D spend, now at 6% of sales (₹88 crore in Q1), is heavily skewed toward Complex Gx, oncology, and peptides.
Financial snapshot: broad‑based growth and a fortified balance sheet
The latest quarter extends a run of sequential revenue growth that began in early FY26. The table below, drawn from the company’s consolidated financials, highlights the consistent top‑line and margin expansion.
| Period (Consolidated) | Revenue (₹ crore) | EBITDA Margin | PAT (₹ crore) |
|---|---|---|---|
| Q4 FY25 | 1,197.4 | 23.8% | 152.0 |
| Q1 FY26 | 1,210.1 | 19.6% | 112.6 |
| Q2 FY26 | 1,297.0 | 21.4% | 130.6 |
| Q3 FY26 | 1,387.9 | 21.9% | 150.2 |
| Q4 FY26 | 1,470.6 | 25.6% | 201.6 |
| Q1 FY27 | 1,476.8 | 23.1% | 179.96 |
The EBITDA margin for Q1 FY27 was 23.1%, moderating from the exceptionally strong 25.6% in Q4 FY26 but still 350 basis points above the 19.6% recorded a year earlier. Profit after tax grew 59.8% YoY.
Cash generation was robust: cash flow from operations in the quarter rose to ₹387.4 crore, up from ₹280.6 crore in Q1 FY26, driven by improved profitability and working‑capital discipline. That, combined with an equity raise of ₹667.5 crore in FY26, helped reduce net debt to just 0.07 times annualised EBITDA, down from 0.34 times at the end of FY26.
Pipeline and regulatory catalysts: first‑to‑file wins and site approvals
Granules continues to build a high‑value pipeline. In Q1 FY27, it filed 5 finished‑dosage dossiers and 4 API dossiers. The company secured a second sole first‑to‑file opportunity—Sodium Oxybate ER, with a brand market size of $267 million. Alongside, 25 ANDAs are awaiting approval, targeting a combined addressable market of around $40 billion (brand plus generic).
The quality‑compliance front is also clearing. The GPI facility in Virginia received a Voluntary Action Indicated (VAI) classification from the US FDA after its April 2026 inspection, and the company obtained an EU GMP certificate for its Genome Valley formulation site. These approvals remove overhangs and are expected to accelerate new product launches.
The Genome Valley facility, which adds 10 billion dosage units (a 40% increase in formulation capacity), is now shipping prescription products to the US. Management had previously guided that the site would be fully ramped up by Q1 FY27. The plant remains in a ramp‑up phase but is already contributing incremental revenue.
Peptides CDMO: lumpy quarter, but on the expected trajectory
The Peptides CDMO business—built through the acquisition of Swiss‑based Senn Chemicals—posted an EBITDA loss of ₹12.4 crore in Q1 FY27, reversing the marginal profit of ₹1.5 crore in Q4 FY26. The company attributed this to project‑milestone timing, a factor management had flagged repeatedly. On the Q4 FY26 call, Chief Strategy Officer Sanjay Kumar warned that “individual quarters may vary, depending on customer milestone and shipment timing,” while emphasising the goal of annual PAT positivity for FY27.
The swing from loss to profit and back again is characteristic of a project‑driven contract‑development business. The pipeline includes TFA‑free peptide chemistries for cosmetics and active projects with pharmaceutical customers. The company still expects the segment to deliver positive EBITDA on a full‑year basis, and the narrower loss compared to the ₹20‑24.8 crore quarterly losses seen in FY26 suggests the platform is progressing along its integration curve.
Geographic diversification: Europe and rest‑of‑world gather pace
Revenue from North America still dominates (₹1,056.3 crore), but Europe and Rest of World (RoW) are growing much faster. In Q1 FY27, Europe rose 51% YoY to ₹243.6 crore and RoW surged 56% to ₹176.8 crore. The company is “evolving from a North America‑centric model to a multi‑region value platform,” with complex‑Gx launches and peptide CDMO engagements driving the expansion.
This diversification strategy was endorsed by earlier management commentary: “our increasing focus on ROW markets supports our strategy to diversify beyond the US and Europe,” Chairman Chigurupati said on the Q3 FY26 call. With a growing dossier pipeline for European markets and API/PFI demand picking up in RoW, the revenue base is becoming more balanced, reducing dependence on any single geography.
---